Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Artificial intelligence (AI) is revolutionising science and healthcare, and cancer research is no exception. Multiple AI approaches have been used for cancer diagnosis and prognosis, drug target prediction, and the analysis of tumour composition from multimodal data, amongst many other tasks.
With this cross-journal Collection, the editors at Nature Communications, npj Digital Medicine, npj Precision Oncology, Communications Biology, Communications Medicine, and Scientific Reports invite submissions with a focus on AI in cancer. We welcome papers covering recent advances in the development and application of AI techniques – including machine learning and deep learning methods – with the purpose of deciphering cancer biology, improving diagnosis, prognosis and treatment, and leveraging the vast amounts of available datasets for the benefit of cancer patients.
This Collection supports and amplifies research related to SDG 3: Good Health and Well-Being.
Successful human-AI collaboration could greatly contribute to breast cancer mammographic screening. Here, the authors use a large-scale retrospective mammography dataset to simulate and compare five plausible AI-integrated screening pathways, finding optimal ways in which human-AI collaboration could be implemented in real-world settings.
The distinction of liver lesions is critical for the accurate diagnosis and treatment of liver cancer. Here, the authors develop LiLNet, a deep learning-based system to identify focal liver lesions as well as benign and malignant liver tumours from CT images with high accuracy across multiple patient cohorts.
Federated learning (FL) has emerged as a potential solution to train machine learning models in multiple clinical datasets while preserving patient privacy. Here, the authors develop an MRI-based FL platform for pediatric posterior fossa brain tumors—FL-PedBrain—and evaluate it on a diverse multi-center cohort.
Renal cell carcinoma consists of several subtypes, and recurrence is highly dependent on subtype. Here, the authors develop a multi-classifier using imaging, lncRNA and clinical data to predict recurrence in papillary renal cell carcinoma.
Supervised deep learning models hold promise for the interpretation of histology images, but are limited by cost and quality of training datasets. Here, the authors develop a self-supervised deep learning method that can automatically discover features in cancer histology images that are associated with diagnosis, survival, and molecular phenotypes.
Sahlsten et al. systematically evaluate two Bayesian deep learning methods and eight uncertainty measures for the segmentation of oropharyngeal cancer primary gross tumor volume with a multi-institute PET/CT dataset. The uncertainty-aware approach can accurately predict the segmentation quality that enables automatic segmentation quality control.